Comparison of Vildagliptin and Pioglitazone in Korean Patients with Type 2 Diabetes Inadequately Controlled with Metformin

다국어 초록 (Multilingual Abstract)

Background: We compared the efficacies of vildagliptin (50 mg twice daily) relative to pioglitazone (15 mg once daily) as an addon treatment to metformin for reducing glycosylated hemoglobin (HbA1c) levels in Korean patients with type 2 diabetes.
Methods: The present study was a multicenter, randomized, active-controlled investigation comparing the effects of vildagliptin and pioglitazone in Korean patients receiving a stable dose of metformin but exhibiting inadequate glycemic control. Each patient underwent a 16-week treatment period with either vildagliptin or pioglitazone as an add-on treatment to metformin.
Results: The mean changes in HbA1c levels from baseline were –0.94% in the vildagliptin group and –0.6% in the pioglitazone group and the difference between the treatments was below the non-inferiority margin of 0.3%. The mean changes in postprandial plasma glucose (PPG) levels were –60.2 mg/dL in the vildagliptin group and –38.2 mg/dL in the pioglitazone group and these values significantly differed (P=0.040). There were significant decreases in the levels of total, low density lipoprotein, high density lipoprotein (HDL), and non-HDL cholesterol in the vildagliptin group but increases in the pioglitazone group. The mean change in body weight was –0.07 kg in the vildagliptin group and 0.69 kg in the pioglitazone group, which were also significantly different (P=0.002).
Conclusion: As an add-on to metformin, the efficacy of vildagliptin for the improvement of glycemic control is not inferior to that of pioglitazone in Korean patients with type 2 diabetes. In addition, add-on treatment with vildagliptin had beneficial effects on PPG levels, lipid profiles, and body weight compared to pioglitazone.

참고문헌 (Reference)

1 Profit L, "Vildagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus" 3 : 13-30, 2008

2 Cariou B, "Thiazolidinediones and PPARgamma agonists: time for a reassessment" 23 : 205-215, 2012

3 Willson TM, "The PPARs:from orphan receptors to drug discovery" 43 : 527-550, 2000

4 김대중, "The Epidemiology of Diabetes in Korea" 대한당뇨병학회 35 (35): 303-308, 2011

5 김철식, "Prevalence, Awareness, and Management of Obesity in Korea: Data from the Korea National Health and Nutrition Examination Survey (1998–2011)" 대한당뇨병학회 38 (38): 35-43, 2014

6 Inzucchi SE, "Management of hyperglycemia in type 2 diabetes, 2015: a patientcentered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes" 38 : 140-149, 2015

7 Charbonnel B, "Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes" 48 : 1093-1104, 2005

8 Jin SM, "Lobeglitazone and pioglitazone as add-ons to metformin for patients with type 2 diabetes: a 24-week, multicentre, randomized, double-blind, parallel-group, active-controlled, phase III clinical trial with a 28-week extension" 17 : 599-602, 2015

9 Cuthbertson J, "Investigation of the effect of oral metformin on dipeptidylpeptidase-4 (DPP-4) activity in type 2 diabetes" 26 : 649-654, 2009

10 Kim DJ, "Insulin secretory dysfunction and insulin resistance in the pathogenesis of Korean type 2 diabetes mellitus" 50 : 590-593, 2001

11 Fukushima M, "Insulin secretion and insulin sensitivity at different stages of glucose tolerance:a cross-sectional study of Japanese type 2 diabetes" 53 : 831-835, 2004

12 Green BD, "Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1" 547 : 192-199, 2006

13 Lindsay JR, "Inhibition of dipeptidyl peptidase IV activity by oral metformin in type 2 diabetes" 22 : 654-657, 2005

14 Ahren B, "Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year" 28 : 1936-1940, 2005

15 International Diabetes Federation, "IDF diabetes atlas"

16 Guariguata L, "Global estimates of diabetes prevalence for 2013 and projections for 2035" 103 : 137-149, 2014

17 Stumvoll M, "Glitazones: clinical effects and molecular mechanisms" 34 : 217-224, 2002

18 Bolli G, "Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study" 10 : 82-90, 2008

19 Mannucci E, "Effects of metformin on glucagon-like peptide-1 levels in obese patients with and without type 2 diabetes" 17 : 336-342, 2004

20 Migoya EM, "Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1" 88 : 801-808, 2010

21 Schwartz AV, "Diabetes, TZDs, and bone: a review of the clinical evidence" 2006 : 24502-, 2006

22 석지혜, "Current Status of Prescription in Type 2 Diabetic Patients from General Hospitals in Busan" 대한당뇨병학회 38 (38): 230-239, 2014

23 Lago RM, "Congestive heart failure and cardiovascular death in patients with prediabetes and type 2diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials" 370 : 1129-1136, 2007

24 Bolli G, "Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin" 11 : 589-595, 2009

25 Kaur K, "Comparison of efficacy of add-on therapy of vildagliptin versus pioglitazone among type 2 diabetes mellitus patients inadequately controlled on dual therapy of metformin plus sulfonylurea" 5 : 77-81, 2014

26 Takihata M, "Comparative study of sitagliptin with pioglitazone in Japanese type 2 diabetic patients: the COMPASS randomized controlled trial" 15 : 455-462, 2013

27 Hermansen K, "Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus" 30 : 1127-1142, 2007

28 Moller JB, "Body composition is the main determinant for the difference in type 2 diabetes pathophysiology between Japanese and Caucasians" 37 : 796-804, 2014